Ketoacidosis is primarily a type 1 diabetes problem because people with type 1 produce little to no insulin at all, and it takes only a tiny amount of insulin to keep ketone production in check. People with type 2 diabetes almost always retain enough insulin secretion to prevent ketones from spiraling out of control, even when their blood sugar is poorly managed. The amount of insulin needed to suppress fat breakdown and ketone production is far less than the amount needed to control blood sugar, which is why someone with type 2 can have dangerously high glucose yet never tip into ketoacidosis.
How Insulin Keeps Ketones in Check
Your body produces ketones when it breaks down fat for energy instead of using glucose. In the fed state, insulin suppresses ketone production through two main actions: it stops fat cells from releasing fatty acids into the bloodstream, and it blocks the liver from converting those fatty acids into ketone bodies. Without a steady supply of fatty acids arriving at the liver, there’s simply not enough raw material for ketone production to ramp up.
Insulin also suppresses the gene responsible for a key enzyme in the liver’s ketone-producing pathway. So insulin acts as a brake at multiple points: it limits fat release, limits fat processing, and limits the liver’s capacity to manufacture ketones in the first place. When that brake is completely removed, as it is in type 1 diabetes, all three checkpoints fail simultaneously.
Why Type 1 Loses the Safety Net
In type 1 diabetes, the immune system destroys the insulin-producing cells of the pancreas. The result is an absolute insulin deficiency. Without any circulating insulin, fat cells release fatty acids freely, the liver converts them into ketones at full speed, and there’s nothing to slow the process down.
Making things worse, the absence of insulin triggers a surge in counter-regulatory hormones: glucagon, adrenaline, cortisol, and growth hormone. These hormones actively accelerate fat breakdown and ketone production. Experimental evidence in both humans and animals shows that this hormonal surge is necessary to initiate the excessive liver production of ketones that leads to full-blown ketoacidosis. It’s not just the lack of insulin that causes the crisis. It’s the combination of missing insulin and unopposed stress hormones working together.
The body does have a built-in feedback loop: as ketone levels rise, ketones themselves signal fat cells to slow down the release of fatty acids, acting as a natural brake. But in diabetic ketoacidosis, the forces driving fat release (absent insulin, dehydration, and heightened sympathetic nervous system activity) overwhelm this feedback mechanism. Ketone concentrations can exceed 20 mmol/L, far beyond what the body’s self-regulation can handle.
Why Type 2 Retains Protection
Type 2 diabetes is fundamentally a different metabolic situation. The core problem is insulin resistance: cells respond poorly to insulin, so blood sugar rises. But the pancreas is still producing insulin, often in large amounts. This residual insulin secretion is enough to keep fat cells from dumping fatty acids uncontrollably and to prevent the liver from ramping up ketone synthesis.
The American Diabetes Association describes this clearly: in the type 2 equivalent of a hyperglycemic crisis (called hyperosmolar hyperglycemic state), there is a residual amount of insulin that minimizes ketosis but does not control hyperglycemia. That’s the key distinction. Blood sugar can climb to extreme levels because insulin resistance prevents glucose from entering cells efficiently. But even a small amount of circulating insulin is enough to suppress the fat-breakdown pathway that feeds ketone production.
Normal Ketone Levels vs. Ketoacidosis
It helps to understand the scale. Normal blood ketone levels sit below 0.6 mmol/L. Nutritional ketosis from fasting or a low-carb diet typically produces levels of 0.5 to 3.0 mmol/L, which healthy insulin signaling keeps from climbing further. Diabetic ketoacidosis, by contrast, involves ketone levels above 3.0 mmol/L and often far higher, paired with a drop in blood pH below 7.3 and bicarbonate levels below 15 mEq/L.
The acid buildup is what makes ketoacidosis dangerous. Ketone bodies are acidic, and when they accumulate faster than the body can buffer or excrete them, blood becomes increasingly acidic. Both the high glucose and high ketone levels drive water and electrolytes out through the kidneys. Potassium losses alone can range from 3 to 15 mmol per kilogram of body weight, and sodium losses from 5 to 13 mmol/kg. This combination of acidosis, dehydration, and electrolyte depletion is what makes DKA a medical emergency.
When Type 2 Diabetes Can Cause Ketoacidosis
The general rule that type 2 diabetes doesn’t cause ketoacidosis has important exceptions. One increasingly recognized cause involves a class of medications called SGLT2 inhibitors (sold under names like empagliflozin and dapagliflozin). These drugs work by forcing the kidneys to excrete excess glucose into the urine. The resulting glucose loss mimics a state of carbohydrate starvation, which shifts the glucagon-to-insulin ratio and pushes the body toward fat burning and ketone production. SGLT2 inhibitors also directly stimulate glucagon release from the pancreas, further worsening the hormonal imbalance, and they increase ketone reabsorption from the kidneys.
DKA from SGLT2 inhibitors is uncommon, occurring at a rate of roughly 0.16 to 0.76 events per 1,000 patient-years in people with type 2 diabetes. But it carries an unusual twist: blood sugar may remain below 250 mg/dL, a condition called euglycemic DKA. Because glucose isn’t dramatically elevated, the diagnosis can be missed. The risk is highest when a trigger like infection, surgery, prolonged fasting, or heavy alcohol use is layered on top of the medication.
There is also a distinct condition called ketosis-prone type 2 diabetes, most commonly seen in African, African American, Hispanic, and young adult Japanese populations. People with this form are typically middle-aged and obese with a family history of type 2 diabetes, but they present with full DKA, usually triggered by a physiological stressor like an infection. What appears to happen is a temporary, severe impairment of insulin secretion on top of existing insulin resistance. Once the trigger is treated and insulin therapy is started, their insulin-producing cells often recover, and many can eventually stop insulin altogether.
The Core Difference in One Concept
The threshold of insulin needed to suppress ketone production is remarkably low compared to the amount needed to control blood sugar. Think of it as two different jobs with two different pay grades. Keeping fat cells from flooding the bloodstream with fatty acids requires only a small paycheck of insulin. Getting glucose into resistant muscle and liver cells requires a much larger one. People with type 2 diabetes can fail at the second job while still succeeding at the first. People with type 1 diabetes, producing no insulin at all, fail at both.
This is also why someone with type 1 diabetes can develop ketoacidosis surprisingly fast, sometimes within hours of missing insulin doses, while someone with type 2 can run high blood sugars for days without producing dangerous ketone levels. The protective floor of residual insulin in type 2 diabetes is small, but it’s enough to keep the ketone pathway suppressed under most circumstances.